Urgent.News

600+ sources. One page. See who else covered it.

Editions

Finance & Markets

Cardiac drug developer Braveheart banks more than $382M in IPO

Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately be more than $1 billion from public investors.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at biopharmadive.com →

More in Finance & Markets

More from Thursday 6 August →